Navigation Links
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib,Combination in Non-Small Cell Lung Cancer Presented at American,Association of Cancer Research Annual Meeting

imately 75-80% of NSCLCs," commented Jean Nichols, Ph.D., Executive Vice-President and Chief Scientific Officer at Gloucester.

"The preclinical synergy seen in this study provides a strong rationale for conducting clinical studies of the combination. If similar results are seen clinically, the potential exists to substantially increase the use of TKIs such as erlotinib in a broader population of lung cancer," she concluded.

About Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths worldwide. There are over 1.2 million cases of lung cancers every year in the world, and 1.1 million people will die from their disease. Non-small cell lung cancer accounts for approximately 80% of lung cancer.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops an
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/25/2014)... PORT OF SPAIN, Trinidad and Tobago , ... Drugs Division of the Trinidad & Tobago Ministry ... the market, an innovative therapy that significantly increases the ... indicated for patients infected with the genotype 1 ... under the trade brand INCIVO®. ...
(Date:7/25/2014)... -- Solanbridge Group Inc (OTC: SLNX) is pleased to announce ... and the Letter of Intent issued on July 11, ... Agreement. Charles R. Shirley , Managing ... Mr. David Pecoraro and Buzznbrewz.com join SLNX,s ... sector and developed a tremendous network of contacts who ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
(Date:7/25/2014)... 25, 2014 In recent years, men have ... to reverse the symptoms associated with age-related testosterone decline. Amid ... large, a new case study from Renew Man ... testosterone therapy using bioidentical hormones. , The case study ... Seattle who found himself beginning to feel the effects of ...
(Date:7/25/2014)... As reported by the Statesman Journal in the article ... police in Salem, MA as well as several other states ... epidemic that has taken many lives during the past couple ... in which police were able to make two arrests by ... to be the victim and claiming to want to buy ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Seniors are more ... people, a new study finds. "Almost any type ... from the age of 25 on," study co-author Randi ... a university news release. However, Martin said, this ... on processing in older adults compared with younger adults. ...
(Date:7/25/2014)... Island (PRWEB) July 25, 2014 Reproductive ... to announce that Dr. Kerri Luzzo, Lead Physician at ... Award" for her professional accomplishments in fertility care and ... , At the 10th Annual PBN Awards ceremony held ... Island, 40 of the most highly regarded, emerging leaders ...
(Date:7/25/2014)... News) -- The human brain can preserve oxygen to ... study finds. Although dehydration significantly reduces blood ... that the brain compensates by increasing the amount of ... has helped us understand a lot more about how ... conditions," study first author Steven Trangmar, a researcher at ...
Breaking Medicine News(10 mins):Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2
... Scientists at the University of Liverpool have identified high levels ... may suggest why they live longer than other rodents and ... recently generated the first whole-genome sequencing data of the naked ... years and is resistant to cancer - to understand its ...
... , THURSDAY, Nov. 3 (HealthDay News) --,When an ... can suffer fatal injuries, a new report suggests. That,s ... associated with these natural disasters occur when bridges and roads ... is disrupted, according to a group of Boston researchers who ...
... News) -- Smokers are more likely to kick the habit ... processes emotions was damaged by the stroke, researchers say. ... smoking before they had a stroke were much more likely ... about quitting. These findings may lead to new ways ...
... , THURSDAY, Nov. 3 (HealthDay News) -- A new ... calls into question the widespread practice of classifying children ... and their IQ scores, researchers report. ... many school systems in the United States to determine ...
... PHILADELPHIA - A research group at the Perelman School ... John Lynch, MD, PhD, assistant professor of Medicine in ... Institute (NCI) grant to establish a Barrett,s esophagus translational ... Timothy Wang) and the Mayo Clinic (led by Dr. ...
... federal government is investing billions of dollars to encourage ... technology so that all Americans can benefit from the ... about potential harm are emerging as providers increasingly rely ... information technologies to deliver care. ,HEALTH IT ...
Cached Medicine News:Health News:Scientists identify genes that may signal long life in naked mole-rats 2Health News:Earthquakes Put Millions of Lives, Major Cities at Risk 2Health News:Some Smokers More Likely to Quit After Stroke Than Others 2Health News:Study Finds No Link Between Dyslexia and IQ 2Health News:Penn collaborates on $8 million Barrett's esophagus research network 2Health News:Penn collaborates on $8 million Barrett's esophagus research network 3
... magnification. The true benefit of this system ... focal clarity is made possible to to ... aluminum bar and individual pupillary adjustments provides ... focal alignment, eliminating headache and eyestrain., ,Ideal ...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: